Health Experts See Malaysia As Potential Biotech Leader
This article was originally published in PharmAsia News
A leading health care consultant on Southeast Asia says Malaysia could become a leader in medical biotechnology if it focuses efforts on a few priorities for applying the technology. Siddhart Singh, consultant for Asia-Pacific Healthcare, said in an interview Malaysia has the potential because of its already-developed biotech hub, its bio-diversity and its low-cost production capability, according to Frost & Sullivan, a research and consulting firm. Since 2006, Malaysia has counted 20 companies registered with its BioNexus group as health care firms. Singh pointed to developing innovative diagnostic techniques and increasing the country's ability to conduct outsourced clinical research among important areas to consider in seeking further growth. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.